H. Lundbeck Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
H. Lundbeck Bundle
Visual. Strategic. Downloadable.
Curious where H. Lundbeck’s products land—Stars, Cash Cows, Dogs, or Question Marks? This snapshot teases the story; buy the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a clear roadmap for resource allocation. You’ll receive a ready-to-use Word report plus an Excel summary so you can present and act fast. Purchase now for strategic clarity that saves time and money.
Stars
Vyepti (eptinezumab)
Vyepti (eptinezumab) — FDA approved in 2020 — delivers IV migraine prevention with rapid onset demonstrated as early as day 1 in PROMISE-2, driving strong uptake in US and EU centers and expanding awareness. The hospital/infusion-site delivery creates a durable moat once embedded, but sustained promotion and payer access muscle are required; share gains are already material and the asset can scale into a franchise.
Rexulti (incl. agitation in Alzheimer’s)
Label expansion for Rexulti opened treatment to an estimated 2.7M US Alzheimer's patients with agitation (40% of ~6.7M people with AD in 2024), tapping a large, under-treated population with urgent need. Prescriber familiarity from MDD/schizophrenia and ~$1.4B global Rexulti sales in 2024 accelerate uptake, but market education and payer negotiations remain heavy lifts. Growth runway looks long as clinical use normalizes; invest now to cement leadership before fast followers enter.
Trintellix / Brintellix (vortioxetine)
Trintellix/Brintellix (vortioxetine) remains a Star for H. Lundbeck thanks to its differentiated cognitive profile, supporting continued relevance in a crowded antidepressant class; FY 2024 net sales were about USD 1.1 billion, driven by uptake in US and select EU markets. Growth persisted in targeted geographies despite generic pressure, but the brand still requires active promotion and payer engagement to defend share. Managed well, it can transition toward Cash Cow status as markets mature.
Abilify Maintena (LAI antipsychotic)
Abilify Maintena (aripiprazole LAI) sits in Stars: long-acting injectables gained traction in serious mental illness, with LAIs representing an expanding share of schizophrenia maintenance therapy by 2024 and strong brand trust for Abilify Maintena supporting adherence and predictable revenue momentum.
High market growth plus Lundbeck/Otsuka’s high share create stable near-term top-line visibility; continued HCP education and evolving site-of-care models (clinic, home, infusion centers) amplify uptake and access.
- Approved: US 2013, EU 2014; marketed via Otsuka/Lundbeck partnership
- LAI market growth: mid-single-digit to low-double-digit CAGR through 2024 (segment expansion)
- Commercial strengths: strong brand recognition, adherence gains, expanding site-of-care models
- Execution levers: HCP education, payer access tuning, REMS/site partnerships
US Neuroscience Specialty Footprint
US Neuroscience specialty footprint is a strategic asset: a commercial engine centered on CNS specialists accelerates scale and enables complex launches such as infusions and long-acting injectables, driving higher pull-through and persistence in therapy. Network effects manifest in prescribing momentum and patient retention, supporting durable market access and payer engagement. Continued investment sustains the flywheel and maximizes lifetime product value.
- Commercial engine: specialist-led salesforce
- Launch support: infusions and LAIs
- Outcomes: improved pull-through and persistence
- Strategy: ongoing investment to sustain flywheel
Rapid IV uptake since 2020; label expansion adds 2.7M US eligibles
Vyepti driving rapid IV uptake since 2020 with strong US/EU adoption. Rexulti label added ~2.7M eligible US AD agitation patients in 2024, accelerating sales. Trintellix net sales ~USD 1.1B in 2024; Abilify Maintena benefits from rising LAI share (mid-single to low-double-digit CAGR to 2024).
| Product | 2024 metric | Note |
|---|---|---|
| Vyepti | Uptake strong | IV infusion moat |
| Rexulti | 2.7M elig. | Label expansion |
| Trintellix | USD 1.1B | Defend vs generics |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of H. Lundbeck's portfolio, identifying Stars, Cash Cows, Question Marks and Dogs with strategic actions.
Customizable Excel Spreadsheet
One-page H. Lundbeck BCG Matrix pinpointing portfolio pain points for faster strategic decisions and resource fixes.
Cash Cows
Cipralex / Lexapro (escitalopram)
Cipralex/Lexapro (escitalopram), launched in 2002 with patent expiry around 2012, has a large installed base and predictable volumes requiring lean promotion; mature markets yield steady scripts that keep cash flowing. Optimize pricing, secure supply and target tenders rather than heavy push, preserving margin. Milk the cash to fund pipeline investments and next bets.
Ebixa (memantine, ex‑US)
Ebixa (memantine, ex‑US) remains Lundbeck’s legacy Alzheimer’s cash cow with stable demand across multiple markets, supporting consistent ex‑US revenues despite limited growth; global dementia prevalence exceeded 55 million in 2020 and continues rising, underpinning baseline need for symptomatic therapies. Minimal promotion, focus on contracting and COGS keeps margins steady while newer AD treatments ramp.
Abilify Maintena (stable markets)
Abilify Maintena (approved 2013 in EU/US) remains a stable cash cow for H. Lundbeck in mature markets, with a flattening revenue curve but sticky monthly volumes due to once-monthly dosing. High adherence and low patient churn sustain predictable margin contribution, allowing predictable free cash flow. Maintain high service levels and avoid heavy promotional spend; it funds bolder R&D and M&A moves.
Trintellix (mature geos)
Trintellix in mature geos has peaked and in 2024 generated DKK 4.5bn in net sales, reliably throwing off cash with modest commercial support; defend core prescribers, trim low-return spend, and ride the tail for profitability. Lifecycle tweaks and payer maintenance matter more than splash campaigns—efficiency equals yield here.
- 2024 sales: DKK 4.5bn
- Focus: core prescribers retention
- Cut: non-working marketing spend
- Priority: lifecycle tweaks, payer maintenance
Established Hospital Accounts
Established hospital accounts for Lundbeck act as cash cows: once on protocol persistence exceeds 80% and switching is rare, securing predictable volumes. Low-cost account management and tight inventory control sustain margins, with hospital channels typically yielding higher contribution per unit. Surplus cash is directed to fund high-growth neurology launches and late-stage R&D.
- Persistence >80%
- Low-cost management sustains volumes
- Tight inventory improves contribution
- Surplus funds high-growth launches
Steady cash flows from legacy antidepressants, dementia care, monthly injectables
Cipralex/Lexapro (launched 2002) yields steady volumes with lean promotion. Ebixa sustains ex‑US revenue; global dementia >55m in 2020. Abilify Maintena (EU/US approval 2013) delivers sticky monthly cash. Trintellix generated DKK 4.5bn net sales in 2024, funding R&D.
| Product | Role | 2024 metric |
|---|---|---|
| Cipralex | Cash cow | Launched 2002 |
| Ebixa | Cash cow (ex‑US) | Dementia >55m (2020) |
| Abilify Maintena | Cash cow | Approved 2013 |
| Trintellix | Cash cow | DKK 4.5bn sales (2024) |
| Hospitals | Channel cash cow | Persistence >80% |
What You See Is What You Get
H. Lundbeck BCG Matrix
The file you’re previewing is the exact H. Lundbeck BCG Matrix report you’ll receive after purchase. No watermarks, no placeholders—just a fully formatted, analysis-ready document crafted for strategic clarity. Once bought, the same file is instantly downloadable and editable for presentations or planning. It’s the final deliverable, designed by strategy pros and ready to use.
Dogs
Northera (droxidopa)
Northera (droxidopa), FDA‑approved in 2014 for neurogenic orthostatic hypotension, now sits in the BCG Dogs quadrant as generic pressure and narrowing payer access have eroded share. Turnaround attempts are costly and historically seldom durable. Best course: disciplined harvesting or divestiture to free field resources for higher‑velocity assets.
Xenazine (tetrabenazine)
Xenazine (tetrabenazine) sits in Lundbeck's BCG Dogs quadrant: generic competitors and newer agents have eroded uptake, and the Huntington's disease population remains small (~5–10 per 100,000 globally in 2024). Low market growth and declining share make it a cash trap; maintain minimal support and evaluate divestment. Hard to justify incremental R&D or marketing spend.
Sabril (vigabatrin)
Sabril (vigabatrin) sits in a late‑lifecycle position within Lundbeck’s BCG matrix; FDA approval in 2009 brought a permanent REMS requiring regular visual field monitoring due to retinal toxicity. Revenue has largely drifted sideways amid generic headwinds and limited label expansion. Preserve value through tight cost control and orderly wind‑down rather than chasing volume with promotional spend.
Cipramil (citalopram)
Cipramil (citalopram) is a legacy SSRI facing extensive generic substitution and negligible promotional ROI; maintain only essential supply commitments and avoid new commercial investment. Redeploy capital to growth assets within Lundbeck’s portfolio where marginal returns exceed low-maintenance generics.
Selincro (nalmefene)
Selincro (nalmefene) sits squarely in Dogs: clear medical need in AUD—WHO estimates ~283 million people with alcohol use disorders—yet reimbursement gaps and clinical inertia have kept adoption low. Market share remains marginal versus established treatments, leaving limited growth prospects. Lundbeck should consider sunset or niche-partnering rather than costly relaunches.
- Reimbursement barriers
- Clinical inertia limits uptake
- Marginal market share
- Prefer sunset/partner over pricey relaunch
Harvest/divest low-growth, high-generic neurology assets; redeploy to growth franchises
Lundbeck Dogs: low-growth, high-generic pressure assets—Northera, Xenazine, Sabril, Cipramil, Selincro—recommend harvest/divest, minimal support, redeploy capital to growth franchises.
| Product | 2024 metric | Action |
|---|---|---|
| Northera | Post-2014 approval; payer squeeze 2024 | Harvest/divest |
| Xenazine | HD prevalence ~5–10/100,000 (2024) | Minimal support |
| Sabril | REMS since 2009; stagnant revenue 2024 | Wind-down |
| Cipramil | Generic substitution widespread 2024 | Supply only |
| Selincro | AUD global burden 283M (WHO 2024) | Sunset/partner |
Question Marks
New Alzheimer’s programs
Alzheimer’s is a high-growth area with massive unmet need—55 million people with dementia in 2020, rising to an estimated 139 million by 2050, and global dementia costs hit US$1 trillion in 2019 (projected near US$2 trillion by 2030). New drugs can flip a Question Mark to a Star: lecanemab showed ~27% slowing in Clarity AD, while Aduhelm launched at US$56,000/year (cut to US$28,200). The space is crowded and costly; efficacy/safety/practicality must clearly differentiate or programs sink fast, so decisions are binary: scale investment aggressively or cut clean.
Next‑gen Parkinson’s assets
Next‑gen Parkinson’s assets span progression‑modifying and symptom‑focused approaches, addressing a global patient pool of ~10 million (2024) and a therapeutics market growing at an estimated mid‑single‑digit CAGR (~5% through 2030). Market growth is solid but commercial share is the hurdle for Lundbeck. Early biomarker signals and patient‑reported outcomes will determine go/no‑go decisions. Fund promising assets rapidly and shelve the rest to preserve capital.
Migraine lifecycle extensions
New indications, geos and IV/SC delivery models can extend the eptinezumab Vyepti franchise into episodic and chronic pools; migraine affects ~1 billion people (≈15% global prevalence), and the global migraine therapeutics market exceeded $5bn in 2024. Competition from other CGRP mAbs is intense, driving price and access pressure; payers demand real-world outcomes and head-to-head evidence. Invest selectively where reimbursement precedent exists and outcomes justify list price.
Novel LAI formulations
Novel LAI formulations sit as Question Marks for H. Lundbeck: LAI use in schizophrenia rose to roughly 15–30% across markets in 2023–24, driven by convenience and durability; 3-month LAIs cut injections from 12 to 4 annually (≈66% fewer clinic visits). If administration or dosing is meaningfully better, uptake can spike; without a clear clinical or operational edge, adoption stalls. Prioritise assets that shorten clinic time or demonstrably boost adherence.
- Reduce clinic burden: 3-month dosing reduces visits ~66%
- Adherence impact: LAIs linked to lower relapse vs oral therapy in real-world studies
- Commercial focus: back candidates with clear dosing/admin advantage
Digital / RWE‑enabled CNS solutions
Companion tools and RWE platforms can boost adherence and access—WHO estimates adherence for chronic conditions around 50%—and digital therapeutics exceeded a $5 billion global market in 2024, but sustainable monetization for CNS solutions remains unproven; pilots report engagement uplifts, yet scaling is the key decision: productize or partner quickly.
- Opportunity: high market growth (> $5bn 2024)
- Clinical need: ~50% adherence gap
- Evidence: pilot engagement uplift; scaling risk
- Decision: productize fast or form partnerships
CNS inflection: prove value fast in Alzheimer's, Parkinson's, migraine & LAIs
Question Marks span high‑growth CNS areas where outcomes or delivery must prove value quickly: Alzheimer’s (55M dementia 2020; 27% slowing with lecanemab) and Parkinson (~10M patients 2024) demand binary scale/cut choices; migraine (market >$5bn 2024) and LAIs (15–30% uptake 2023–24; 3‑month dosing −66% visits) need clear reimbursement/uptake signals.
| Asset | 2024 metric | Key trigger |
|---|---|---|
| Alzheimer’s | 55M (2020); 27% lecanemab | Clinical efficacy vs cost |